2FTD
 
 | | Crystal structure of Cathepsin K complexed with 7-Methyl-Substituted Azepan-3-one compound | | Descriptor: | Cathepsin K, N-[(1S)-1-({[(3S,4S,7R)-3-HYDROXY-7-METHYL-1-(PYRIDIN-2-YLSULFONYL)-2,3,4,7-TETRAHYDRO-1H-AZEPIN-4-YL]AMINO}CARBONYL)-3-METHYLBUTYL]-1-BENZOFURAN-2-CARBOXAMIDE | | Authors: | Yamashita, D.S, Baoguang, Z. | | Deposit date: | 2006-01-24 | | Release date: | 2007-01-30 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (2.55 Å) | | Cite: | Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
J.Med.Chem., 49, 2006
|
|
6UJH
 | |
6UJL
 | |
6UJJ
 | |
6UHY
 | | WDR5 in complex with Myc site fragment inhibitor | | Descriptor: | 1-cyclohexyl-1H-benzimidazole-5-carboxylic acid, WDR5 | | Authors: | Wang, F, Fesik, S.W. | | Deposit date: | 2019-09-29 | | Release date: | 2020-04-15 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (1.26 Å) | | Cite: | Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design.
J.Med.Chem., 63, 2020
|
|
6UHZ
 | | WDR5 in complex with Myc site fragment inhibitor | | Descriptor: | 1-cyclohexyl-1H-benzotriazole-5-carboxylic acid, WDR5 | | Authors: | Wang, F, Fesik, S.w. | | Deposit date: | 2019-09-29 | | Release date: | 2020-04-15 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (1.258 Å) | | Cite: | Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design.
J.Med.Chem., 63, 2020
|
|
1TCX
 | | HIV TRIPLE MUTANT PROTEASE COMPLEXED WITH INHIBITOR SB203386 | | Descriptor: | (2R,4S,5S,1'S)-2-PHENYLMETHYL-4-HYDROXY-5-(TERT-BUTOXYCARBONYL)AMINO-6-PHENYL HEXANOYL-N-(1'-IMIDAZO-2-YL)-2'-METHYLPROPANAMIDE, HIV PROTEASE | | Authors: | Hoog, S.S, Abdel-Meguid, S.S. | | Deposit date: | 1996-06-05 | | Release date: | 1996-12-07 | | Last modified: | 2024-02-14 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
Biochemistry, 35, 1996
|
|
1TCW
 | | SIV PROTEASE COMPLEXED WITH INHIBITOR SB203386 | | Descriptor: | (2R,4S,5S,1'S)-2-PHENYLMETHYL-4-HYDROXY-5-(TERT-BUTOXYCARBONYL)AMINO-6-PHENYL HEXANOYL-N-(1'-IMIDAZO-2-YL)-2'-METHYLPROPANAMIDE, SIV PROTEASE | | Authors: | Hoog, S.S, Abdel-Meguid, S.S. | | Deposit date: | 1996-06-05 | | Release date: | 1996-12-07 | | Last modified: | 2024-02-14 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
Biochemistry, 35, 1996
|
|
8HPB
 | |
8HQB
 | | NMR Structure of OsCIE1-Ubox | | Descriptor: | U-box domain-containing protein 12 | | Authors: | Zhang, Y, Yu, C.Z, Lan, W.X. | | Deposit date: | 2022-12-13 | | Release date: | 2023-12-20 | | Last modified: | 2024-06-12 | | Method: | SOLUTION NMR | | Cite: | Release of a ubiquitin brake activates OsCERK1-triggered immunity in rice.
Nature, 629, 2024
|
|
5H7P
 | | NMR structure of the Vta1NTD-Did2(176-204) complex | | Descriptor: | Vacuolar protein sorting-associated protein VTA1, Vacuolar protein-sorting-associated protein 46 | | Authors: | Shen, J, Yang, Z, Wild, C.J. | | Deposit date: | 2016-11-20 | | Release date: | 2016-12-21 | | Last modified: | 2024-05-15 | | Method: | SOLUTION NMR | | Cite: | NMR studies on the interactions between yeast Vta1 and Did2 during the multivesicular bodies sorting pathway
Sci Rep, 6, 2016
|
|
3Q16
 | |
5H7V
 | |
6PCU
 | |
9D9T
 | | Human norovirus GII.4 Sydney protease R112A mutant in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, IODIDE ION, Peptidase C37 | | Authors: | Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-21 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9DAP
 | | Human norovirus GII.3 protease in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, Genome polyprotein | | Authors: | Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-22 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.71 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9DAJ
 | | Human norovirus GII.4 Sydney protease in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, IODIDE ION, Peptidase C37 | | Authors: | Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-22 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9DF5
 | |
9DEY
 | |
9DAL
 | | Human norovirus GII.3 R112A mutant protease in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, Peptidase C37 | | Authors: | Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-22 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
4E99
 | |
7JPY
 | |
7JQ4
 | | Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI7 | | Descriptor: | 3C-like proteinase, N-[(benzyloxy)carbonyl]-O-tert-butyl-L-threonyl-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide | | Authors: | Yang, K, Liu, W. | | Deposit date: | 2020-08-10 | | Release date: | 2020-12-23 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (1.65 Å) | | Cite: | A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Chemmedchem, 16, 2021
|
|
7JQ3
 | | Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI6 | | Descriptor: | 3C-like proteinase, N-[(benzyloxy)carbonyl]-O-tert-butyl-L-threonyl-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide | | Authors: | Yang, K, Liu, W. | | Deposit date: | 2020-08-10 | | Release date: | 2020-12-23 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Chemmedchem, 16, 2021
|
|
7JPZ
 | | Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI1 | | Descriptor: | (phenylmethyl) N-[(2S)-1-oxidanylidene-1-[[(2S)-1-oxidanyl-3-[(3S)-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]-3-phenyl-propan-2-yl]carbamate, 3C-like proteinase | | Authors: | Yang, K, Liu, W. | | Deposit date: | 2020-08-10 | | Release date: | 2020-12-23 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Chemmedchem, 16, 2021
|
|
